Exciting Clinical Findings from Everads Therapy
Everads Therapy, an innovative biotechnology company in the clinical stage, has recently announced its findings from a groundbreaking first-in-human trial. This study illustrates the safety, feasibility, and comfort of using the Everads Injector to deliver medications straight to the back of the eye via the suprachoroidal space.
Promising Results from the First Group of Patients
The outcomes of the trial were showcased at the esteemed EURETINA Congress, revealing positive insights from the initial patient cohort. This open-label study evaluated the injector’s effectiveness in administering a suspension of triamcinolone acetonide aimed at treating diabetic macular edema (DME). The results underscore both the efficacy of the Everads Injector and its user-friendly nature, highlighting its potential for use in an office setting.
Reflections from the Study's Lead Researcher
Dr. Yoreh Barak, the Head of Retina at Rambam Medical Center and the principal investigator of the study, shared his thoughts on these results. He emphasized how effective and convenient the Everads Injector is in real clinical settings. Dr. Barak pointed out that non-surgical treatment delivery represents a significant step forward towards less invasive and more effective solutions for eye diseases affecting the posterior segment.
Continuing with Patient Recruitment
The initial data from this patient group has received necessary clearance from health authorities, which marks an important step in the clinical trial journey. Encouragingly, Everads Therapy is now focused on recruiting more patients for the next cohort. We can expect to see full trial findings presented at upcoming medical conferences.
CEO's Take on the Trial's Outcomes
Expressing optimism about the clinical results, Moshe Weinstein, the CEO of Everads, pointed out that these findings lay a strong groundwork for future clinical trials. He noted this data not only confirms the technology's validity but also enhances their partnerships with licensing entities and internal programs dedicated to developing groundbreaking treatments for retinal diseases.
Diving Into Suprachoroidal Delivery Technology
Everads’ suprachoroidal delivery technology enables the safe and efficient in-office administration of therapeutic agents to retinal and choroidal tissues. Known for its quick delivery capabilities, this method facilitates the distribution of therapies throughout the eye's posterior pole. Such an approach may transform the treatment landscape for retinal disorders, leading to faster and more effective outcomes for patients.
The Potential for Future Innovations
A wealth of research continues to support the efficiency of Everads Therapy's delivery system. Studies spotlighted by Yoreh Barak and Eclov R have demonstrated the technology’s ability to reach macular regions swiftly, which is crucial for the effective treatment of retinal conditions. With ongoing research efforts and collaborations, Everads stands at the forefront of innovation in retinal health.
About Everads Therapy
Everads Therapy is dedicated to improving treatments for retinal diseases through its unique suprachoroidal delivery platform. By addressing the challenges of traditional methods, Everads aims to enhance the safety and effectiveness of current and potential drug therapies. The company actively engages in collaborative projects relating to gene therapy, cell therapy, and small molecule formulations. Everads originated from DALI Medical Devices, a firm specializing in injectable drug delivery technologies, and operates within RAD Biomed, a leading biotech accelerator. The foundational technologies were developed by Professor Ygal Rotenstreich, highlighting the innovative spirit guiding their mission.
Frequently Asked Questions
What is the main goal of Everads Therapy?
Everads Therapy aims to optimize treatments for retinal diseases using its advanced suprachoroidal delivery technology.
How does the Everads Injector work?
The Everads Injector non-surgically delivers medications into the suprachoroidal space at the back of the eye, specifically targeting retinal conditions.
What conditions are being targeted in the trials?
The initial trials are focusing on treating diabetic macular edema (DME), which significantly impacts vision.
Who leads the investigation on the Everads study?
Dr. Yoreh Barak, who is the Head of Retina at Rambam Medical Center, serves as the principal investigator for this study.
What are the next steps for Everads Therapy?
Everads Therapy is actively recruiting more patients for the next trial cohort, with full trial results expected to be announced soon.
